Account

New to ADSS? Open an
account now to get started.

OR

Already have an account?

Add funds to your ADSS account

Account

New to ADSS? Open an
account now to get started.

Add funds to your ADSS account

Trends & Analysis
News

Tesla shares spike despite earnings miss

News

Gold loses some shine after hitting record highs

News

Avoid the tech wreck with PayPal?

News

Week Ahead Preview: 22nd of April

News

P&G shares rise despite Q3 sales miss

News

Gold continues to shine amid geopolitical worries

Trends & Analysis
News

Tesla shares spike despite earnings miss

News

Gold loses some shine after hitting record highs

News

Avoid the tech wreck with PayPal?

News

Week Ahead Preview: 22nd of April

News

P&G shares rise despite Q3 sales miss

News

Gold continues to shine amid geopolitical worries

Asset Watch

Stay healthy with Johnson & Johnson?

Thursday, June 1, 2023

With artificial intelligence (AI) dominating the news flow, Big Tech has drastically outshined its counterparts in 2023. And though healthcare is one of the worst-performing S&P 500 sectors, out-of-favour assets often outperform when sentiment shifts.

Johnson & Johnson underperformed the S&P 500 by nearly 7% in May. However, Citigroup analysts see a 20% upside and expect J&J to hit $185 after the spinoff of Kenvue. They wrote:

“What remains is world-leading medical technology and pharmaceutical franchises, which can focus R&D (and management energy) on respective pipelines while creating a more cohesive drug/device potential…. In other words, there is momentum at the new, streamlined JNJ.”

The stock’s long-term uptrend remains in place and we’re near levels that could elicit buying pressure. $154 is near the February to September 2020 highs, the January to November 2021 lows, and the early 2023 lows.

J&J’s 50-month MA has acted as long-term support since 2011. And if you analyse the candles, you can see that bullish reversals have occurred near this area. Therefore, with another iteration upon us, the risk-reward looks attractive, given the technical and fundamental setup.

Healthcare was one of the best-performing sectors in 2022, while technology was one of the worst. And while riding momentum can prove profitable, the former has shown the ability to perform in bull and bear markets.

So, does J&J deserve a look, or should you stick with the winners and roll with Big Tech?


Site by Pink Green
© ADSS 2024


Investing in CFDs involves a high degree of risk that you will lose your money due to the use of leverage, particularly in fast moving markets, where a relatively small movement in the price can lead to a proportionately larger movement in the value of your investment. This can result in loses that exceed the funds in your account. You should consider whether you understand how CFDs work and you should seek independent advice if necessary.

ADS Securities LLC (“ADSS”) is authorised and regulated by the Securities and Commodities Authority (“SCA”) in the United Arab Emirates as a trading broker for Over the Counter (“OTC”) Derivatives contracts and foreign exchange spot markets. ADSS is a limited liability company incorporated under United Arab Emirates law. The company is registered with the Department of Economic Development of Abu Dhabi (No. 1190047) and has its principal place of business at 8th Floor, CI Tower, Corniche Road, P.O. Box 93894, Abu Dhabi, United Arab Emirates.

The information presented is not directed at residents of any particular country outside the United Arab Emirates and is not intended for distribution to, or use by, any person in any country where the distribution or use is contrary to local law or regulation.

ADSS is an execution only service provider and does not provide advice. ADSS may publish general market commentary from time to time. Where it does, the material published does not constitute advice, or a solicitation, or a recommendation to a transaction in any financial instrument. ADSS accepts no responsibility for any use of the content presented and any consequences of that use. No representation or warranty is given as to the completeness of this information. Anyone acting on the information provided does so at their own risk.